Pustular Psoriasis
Clinical Presentation and Subtypes of Psoriasis
Spevigo approved to treat adolescents with generalized pustular psoriasis in US, China
The FDA has approved an expanded indication for Spevigo injection to treat generalized pustular psoriasis in pediatric patients aged 12 years and older weighing 40 kg or more, Boehringer Ingelheim announced in a press release.
Getting Under the Skin With GPP: Understanding and Treating a Life-Threatening Dermatologic Disorder
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Rapid clearance of generalized pustular psoriasis achieved with single imsidolimab dose
The phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab for the treatment of patients with generalized pustular psoriasis flares met its primary endpoint, AnaptysBio announced in a press release.
Spevigo reduces risk for generalized pustular psoriasis flares in new, late-breaking data
Spevigo significantly outperformed placebo in reducing the risk for generalized pustular psoriasis flares, Boehringer Ingelheim announced in a press release after its late-breaker session at the 25th World Congress of Dermatology.
VIDEO: Insights on treating pustular psoriasis
In this video, Tracey Henslee, CRNP, discusses the treatment of pustular psoriasis, a highlight of this year’s Fall Clinical Dermatology Conference for PAs & NPs held in Orlando.
Imsidolimab showed ‘rapid and sustained’ activity in generalized pustular psoriasis
Three-quarters of patients with generalized pustular psoriasis demonstrated response to treatment with an interleukin-36-targeted therapy as early as 4 weeks, according to a study.
Spesolimab may control generalized pustular psoriasis flares within 24 hours
Spesolimab exhibited rapid control of generalized pustular psoriasis flare symptoms in as little as 24 hours and up to 12 weeks, according to a study.
Spevigo prevents generalized pustular psoriasis flares up to 48 weeks
Spevigo met its primary and key secondary endpoints in a phase 2b trial evaluating the drug for the treatment of adolescents and adults with generalized pustular psoriasis, Boehringer Ingelheim announced in a press release.
Generalized pustular psoriasis lacks advanced treatment options
An unmet need exists to treat generalized pustular psoriasis and its flares, leading many patients to seek emergency or inpatient treatment, according to a study.